Regulatory standard
Bulk Drug Substances in Compounding
Lists; nominations; monographs; active ingredients; 503A/503B distinctions; verification.
This page covers bulk drug substances compounding. It sets out the applicable regulatory framework from named federal sources and separates what those sources establish from what they do not. Every entity-specific field that has not been verified against a primary source renders as Verification Pending rather than being inferred.
Key findings
- Primary focus: Lists.
- Registration with FDA is not FDA approval, and a state licence is not a quality assessment.
- Unverified fields render fail-closed; no badge, score, or ranking is generated from missing data.
- Current and historical records are separated and labelled distinctly.
- Named entities may respond to any record through the right-to-respond process.
| Lists | Verification Pending |
|---|---|
| Nominations | Verification Pending |
| Monographs | Verification Pending |
| Active ingredients | Verification Pending |
| 503a/503b distinctions | Verification Pending |
| Verification. | Verification Pending |
| Federal framework | License Verified FDA sources verified 2026-07-23 |
| Entity-specific data | Verification Pending |
What is established about lists?
For bulk drug substances compounding, lists is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where lists has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about nominations?
For bulk drug substances compounding, nominations is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where nominations has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about monographs?
For bulk drug substances compounding, monographs is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where monographs has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about active ingredients?
For bulk drug substances compounding, active ingredients is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where active ingredients has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about 503a/503b distinctions?
For bulk drug substances compounding, 503a/503b distinctions is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where 503a/503b distinctions has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What does this page establish?
It establishes the framework and the source map for bulk drug substances compounding, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.
What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.
What this means
- The framework governing bulk drug substances compounding is cited to FDA primary sources.
- The record holding each element of lists is named.
- Verification dates are published on every field so staleness is visible.
What this does not mean
- That any entity connected with bulk drug substances compounding is compliant or non-compliant.
- That the absence of a record indicates the absence of an issue.
- That this platform certifies or endorses any facility or preparation.
Status terms on this page follow the platform's published status vocabulary.
- No entity-specific record relating to bulk drug substances compounding has been verified at this snapshot.
- Lists may change without notice to this platform.
- Regulatory positions change through rulemaking, guidance, and enforcement action.
- Records held by different agencies may disagree; conflicts are published as conflicts.
Sources verified for this page — 10 sources
- FDA — Information for Outsourcing Facilitieschecked 2026-07-23
- FDA — Q&A: Outsourcing Facility Registrationchecked 2026-07-23
- FDA — Registered Outsourcing Facilitieschecked 2026-07-23
- FDA — Aligning Federal and State Regulation of Compounderschecked 2026-07-23
- FDA — Outsourcing Facility Feeschecked 2026-07-23
- FDA — Compounded Drug Products That Are Essentially Copieschecked 2026-07-23
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)checked 2026-07-23
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)checked 2026-07-23
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)checked 2026-07-23
- FDA — Outsourcing Facility Fees guidancechecked 2026-07-23
Why bulk drug substances compounding is hard to verify
Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.
First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.
That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.
| Structural feature | Consequence for verification | How this platform handles it |
|---|---|---|
| Split federal and state authority | No single register is complete for any entity | Both systems are named per field, and neither is presented as sufficient |
| Registration precedes inspection | A registration is not evidence of oversight | Registration and inspection are reported as separate facts |
| Records go stale silently | A citation without a date implies currency it may not have | Every field carries its own verification date |
| Observations are not findings | A Form 483 is frequently reported as a violation | Observations and final actions are stored and displayed separately |
| Resolved actions persist online | Closed matters get reported as current | Current and historical status are distinct states, never merged |
Salt forms are not the same active ingredient
Some compounded products have used semaglutide salts — semaglutide sodium or semaglutide acetate — rather than semaglutide base. These are not the same active ingredient as the base form in the approved products, and FDA has stated the salt forms are not appropriate for use in compounding.
This matters for verification because it is checkable. A programme that will not state its exact salt form and concentration cannot be assessed on safety at all, and the refusal is itself the finding.
The same logic applies to any compounded peptide: the identity of what is actually in the vial is the first question, and it is answerable in writing before purchase.
| Form | What it is | Status in compounding |
|---|---|---|
| Semaglutide base | The active ingredient in the approved products | The form approved products use |
| Semaglutide sodium | A salt form, different active moiety | FDA has stated salt forms are not appropriate for compounding use |
| Semaglutide acetate | A salt form, different active moiety | FDA has stated salt forms are not appropriate for compounding use |
Related records in this section
Section hub: Regulatory standards · Methodology · Status definitions · Right to respond
Frequently asked questions
What does this page cover on bulk drug substances compounding?
Lists; nominations; monographs; active ingredients; 503A/503B distinctions; verification.
What is established about lists?
Lists is tracked as part of bulk drug substances compounding. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about nominations?
nominations is tracked as part of bulk drug substances compounding. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about monographs?
monographs is tracked as part of bulk drug substances compounding. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
Which agency holds the record behind bulk drug substances compounding?
Federal registration and inspection records sit with FDA; licensure and discipline sit with the relevant state board of pharmacy. The two systems are separate and must both be checked.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.